Photobiomodulation Market Size | USD 514.5 Mn & 6.8% Growth

A Bright Future: How Photobiomodulation is Shaping the Healthcare Industry (2025-2035)

The global Photobiomodulation (PBM) market size is expected to experience significant growth from 2025 to 2035. Valued at USD 249.5 million in 2024, it is projected to reach USD 514.5 million by 2035, marking a Compound Annual Growth Rate (CAGR) of 6.8%. Photobiomodulation, also known as low-level light therapy (LLLT), is a non-invasive treatment that uses light to stimulate biological processes within cells and tissues, leading to therapeutic benefits. As awareness of its efficacy in managing pain, wound healing, and muscle recovery continues to rise, the market is anticipated to see substantial growth. Key highlights from the market include significant shares held by pain management (41.5% in 2024), infrared light (44.7%), and low-level laser therapy devices (44.5%). The North American region currently leads in market share, while the Asia Pacific region is expected to show the fastest growth due to increasing healthcare investments and medical tourism.

Market Overview

The photobiomodulation industry is undergoing rapid technological advancement, with a shift towards more sophisticated, precise, and personalized therapeutic devices. Innovations such as the Lumaflex Body Pro, which gained FDA Class 2 Certification in 2023, showcase the industry's commitment to safety and efficacy. These next-generation devices offer features such as multiple wavelength options and precise dosage control, improving their versatility and effectiveness across various medical applications. The trend towards personalized medicine is also gaining momentum, as photobiomodulation is tailored to individual patient needs. This is particularly evident in the treatment of neurological and metabolic disorders, where personalized protocols are being developed. Additionally, the sports medicine and fitness sector has become a major growth area for PBM technologies, with athletes and fitness enthusiasts increasingly adopting light therapy for muscle recovery and performance enhancement. As more healthcare providers incorporate PBM into treatment regimens, its scope in addressing chronic conditions, including diabetes-related wounds and musculoskeletal disorders, continues to expand.

To learn more about the global trends impacting the future of Photobiomodulation market research report, Download a PDF Sample

Competitive Landscape

The photobiomodulation market size is highly competitive, with both established players and emerging companies vying for market share through innovation and strategic partnerships. The market is characterized by companies focusing on the development of flexible, multi-application PBM devices, targeting areas such as musculoskeletal pain, dermatology, and neurological disorders. Key players include ALCON Inc., THOR Photomedicine Ltd., BioLight Technologies LLC, Erchonia Corporation, Vielight Inc., Lumenis Ltd., Aspen Laser System, Noveon Inc., LightForce Therapy, and Zynex Medical, among others. These companies are competing through product innovation, geographic expansion, and collaborations with healthcare providers. For instance, companies like Erchonia Corporation are partnering with sports medicine organizations to promote the use of PBM in athletic recovery, while others are introducing portable, user-friendly PBM devices that cater to the growing demand for home-based therapies.

Market Dynamics

The global photobiomodulation market is influenced by several factors, both driving growth and presenting challenges. The aging global population, along with the rising incidence of chronic conditions such as neurological disorders, arthritis, and chronic wounds, is a key driver. Additionally, patients' increasing preference for non-invasive treatments has further fueled the adoption of PBM. However, the market is hindered by several constraints, such as limited clinical evidence, inadequate reimbursement policies, and the high costs associated with advanced PBM devices. Despite these challenges, opportunities for market expansion remain robust, especially in the growing applications of PBM in cosmetic treatments and the rise of home-use devices. Geographically, North America remains the dominant region, driven by technological advancements and funding for research. However, the Asia Pacific region is anticipated to experience the fastest growth, owing to the increase in medical tourism, healthcare investments, and a large patient population in countries such as China and India.

Segmentation

The photobiomodulation market is segmented based on application, wavelength type, end user, and region. In terms of application, the pain management segment holds the largest market share, driven by the rising geriatric population and an increase in arthritis cases worldwide. The wound care segment is expected to be the fastest-growing, particularly due to the increasing global prevalence of diabetes, which often leads to chronic wounds. Regarding wavelength types, the infrared light segment currently dominates due to its effectiveness in treating various medical conditions, while the red light segment is expected to grow rapidly, especially in skin rejuvenation, hair growth, and mental health applications. In terms of end users, specialty clinics currently hold the largest market share, benefiting from their specialized equipment and expertise. However, the home care segment is anticipated to grow the fastest, fueled by increasing awareness of PBM's benefits and the convenience of home-based therapies.

• By Application: Medical (55% share), Cosmetic (30%), Veterinary (15%).
• Device Type: Lasers (60% share), LEDs (35%), Hybrid Systems (5%).
• End-User: Clinics (45%), Hospitals (30%), Homecare (25%).
• Region: North America (45%), Europe (25%), Asia-Pacific (20%), RoW (10%).
  Pain management leads medical applications, while Asia-Pacific’s homecare segment grows at 14% CAGR, driven by Japan’s aging population.

Take Action Now: Secure your Global Photobiomodulation industry today – Purchase Now

Photobiomodulation Market Segments Covered in the report:

By Application:

• Pain Management
• Chronic Pain
• Acute Pain
• Wound Healing
• Surgical Wounds
• Diabetic Ulcers
• Pressure Sores
• Musculoskeletal Disorders
• Tendinitis
• Muscle Strains
• Sprains
• Arthritis
• Osteoarthritis
• Rheumatoid Arthritis
• Dermatology
• Acne Treatment
• Skin Rejuvenation
• Psoriasis and Eczema
• Nerve Regeneration
• Peripheral Neuropathy
• Nerve Injury Recovery
• Dental Applications
• Periodontal Therapy
• Oral Mucositis
• Neurological Disorders
• Traumatic Brain Injury (TBI)
• Stroke Recovery
• Other Therapeutic Areas

By Wavelength:

• Infrared Light (NIR)
• 800-900 nm
• 900-1000 nm
• Red Light
• 600-700 nm
• 700-800 nm
• Others

By Device Type:

• Low-Level Laser Therapy (LLLT) Devices
• Single-Wavelength Lasers
• Multi-Wavelength Lasers
• Light Emitting Diode (LED) Devices
• Portable Devices
• Tabletop Devices
• Full-Body Photobiomodulation Chambers
• Combination Therapy Devices
• Wearable Devices

By End User:

• Hospitals
• Clinics
• Home care settings
• Research Institutes
• Others

Browse in-depth TOC on "Global Photobiomodulation Market Size"

Recent Developments

The PBM market has seen significant developments in recent years, with innovations in product design, strategic partnerships, and research advancements. For instance, in 2023, THOR Photomedicine introduced a handheld PBM device aimed at pain relief and muscle recovery, catering to the growing demand for home-based treatments. In 2024, Erchonia Corporation entered into a partnership with a leading sports medicine organization to promote PBM for athletic recovery. Additionally, new research is expanding PBM's applications to treat a broader range of conditions, including neurodegenerative diseases and mental health disorders. Regulatory approvals and new product launches, such as Iridex's next-generation lasers and PhotoMedex's partnership with Zimmer Biomet, highlight the increasing clinical validation and market adoption of PBM technologies.

Latest Announcements

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

• In August 2024, LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code effective January 1, 2025. The AMA’s CPT Editorial Panel considered and approved the company’s application for a code to report “Photobiomodulation therapy of retina, single session” at the May 2024

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

• In January 2024, Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next- generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration

To know about the vendor offerings - Request a sample report

Conclusion and Future Outlook

The photobiomodulation market is poised for significant growth between 2025 and 2035, driven by technological advancements, increased healthcare demand, and growing consumer awareness of non-invasive therapeutic options. While challenges like high costs and regulatory hurdles persist, opportunities for innovation and market expansion are abundant. The development of affordable, portable, and user-friendly devices, as well as the exploration of new therapeutic applications, will play a crucial role in shaping the future of PBM. As more research supports the efficacy of PBM, its adoption across healthcare, sports, and aesthetics will likely increase. Companies that invest in research, product innovation, and strategic partnerships are well-positioned to capture a share of the rapidly expanding PBM market.